INTRODUCTION
Synthetic heterocycles have widespread interest as herbicides, insecticides, dyes, organic conductors and drugs. Nitrogen-containing heterocycles are of broad pharmaceutical interest and this justifies continuing efforts in the development of structural-activity relationship in this series and of new synthetic strategies.1
Our focused goal here is to approach synthetic routes for several heterocyclic systems based on benzopyran and expected to have biological applications. These heterocycles include pyrrole, pyridine, pyrimidine, oxazine, and triazole residues. Compounds containing fused pyrimidine ring have significant biological activity,2-4 particularly in anti-cancer and antiviral research.2
RESULTS AND DISCUSSION
The condensation between compound 1 and hydrazine hydrate in ethanol at room temperature delivered the pyimidines 2 in 61% yield (Scheme 1). Structural evidence for the reaction product is based on the spectroscopic data. The IR spectrum revealed stretching vibrations at 3332 cm-1 (very br) (OH, NH2, NH) and 1650 cm-1 for C=N. The 1H NMR spectrum showed signals 2.20 (3H, s, CH3), 5.28 (1H, s, 5-H), 6.36 (1H, d, J 0.9, 7-H), 6.51 (1H, d, J 0.9, 9-H), 6.90 (2H, br s, NH2) and 9.78 (1H, br s, OH). Consequently, the imine compound 1 was further condensed with other amines including benzylamine, ethanolamine, methyl carbazate and 2-aminoacetaldehyde dimethyl acetal in absolute ethanol at room temperature and gave the substituted pyrimidines 3a-d in moderate to good yields (Scheme 1). The structures of compounds 3a-d were generally proven on the basis of spectroscopic data and in one case by X-ray crystallography. On examination of the 1H NMR spectrum of compound 3b, it was expected to show two triplets corresponding to the two methylene groups but surprisingly, the spectrum was more complicated and gave four different resonances (each integrating for one proton) indicating the presence of diastereotopic hydrogens from two pairs of hydrogens. A suggested explanation is the formation of an additional ring but X-ray crystal-lographic analysis proved that the structure 3b is the correct one. An explanation for the presence of diastereotopic hydrogens is presumably due to restricted rotation caused by formation of hydrogen bonds which might formed in solution but not in solid state.
Scheme 1.
Fig. 1.X-ray Crystallographic Analysis. 3-(2-Hydroxyethyl)-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol, 3b.
The aminopyrimidine 2 could be used as a key intermediate in heterocyclic synthesis and for substituted heterocyclic systems. Therefore, the coupling between compound 2 and carboxylic acids such as propionic acid (2 equivalents) in DMF using the coupling reagent dicyclohexyl carbodimide (DCC), at room temperature, gave the amide 4 in 64% yield (Scheme 2). An easy and efficient method for preparation of isothiocyanates, important intermediates for organic synthesis, is the reaction between amines and thiophosogene.5 Thus, aminopyrimidine 2 was converted into the isothiocyanate 5 when treated with thiophosogene in dichloromethane in the presence of saturated aqueous potassium carbonate at room temperature for 6 hours and resulted in 59% yield (Scheme 2). IR, 1H NMR, and 13C NMR are all consistent with the proposed structures 4 and 5.
The aminopyrimidine 2 proved to be highly reactive towards various reagents and underwent numerous chemical transformations, resulting in the formation of a wide range of annulated chromenopyrimidine systems.
The synthesis of [1,2,4]triazol-2-one 6 could be accomplished through the interaction of the aminopyrimidine 2 and ethyl chloroformate6 in anhydrous DMF at reflux temperature for 1h and resulted in 69% yield (Scheme 2). Treatment of compound 2 with carbon disulfide in an alcoholic solution of potassium hydroxide at reflux gave the triazolthione 7 6-9 in a poor yield (Scheme 2). The structure was established by the compatible spectroscopic data with the proposed structure. From the 1H NMR spectrum, the product was obtained as a pair of isomers (7 and 7a) (77:23) presumably as a result of Dimroth- type rearrangement. 10-12 As mentioned, the reaction was subjected to conditions which strongly favour formation of the thermodynamically more stable isomer (strong base and heat for long time) which could enhance the isomerization to give only one isomer but still the two isomers were seen; hence this should be the thermodynamic mixture. It worth to mention that the structure 7 was probably the major isomer, this is based on the fact that it is more conjugated and looks like a tetraene; on the other hand structure 7a looks like a triene.
The condensation between the aminopyrimidine 2 and formic acid under reflux temperature readily, after aqueous workup, furnished the expected triazole product as two isomers (8 and 8a), again generated by Dimroth-type rearrangement (Scheme 2). In this case, the two isomers were produced in a 1:1 ratio according to 1H NMR data, the hot acidic conditions used should also generate a thermodynamic mixture 8 and 8a have quite similar chromophores. The 1H NMR data of the reaction product (8 and 8a) displayed signals at 8.55 and 8.75 ppm, which related to the resonances of 5-H in the two structures, a more characteristic proton is 2-H that showed two chemical shift values for both structures at 9.57 and 9.59 ppm.
Scheme 2.
An additional synthetic pathway for constructing triazoles based on the aminopyrimidine compound 2 was established using readily available reagents (a mixture of acetic anhydride and acetic acid) to convert the pyrimidin- 8-ol 2 into triazolo[1,5-c]pyrimidin-9-ylacetate 9 which resulted in 83% yield (Scheme 2).
Interestingly, Dimroth rearrangement worked again and the result was a 1:1 mixture of structures 9 and 9a, strongly thermodynamic conditions were used (acetic anhydride and acetic acid under reflux). Again, very similar chromophores in both isomers so might expect 1:1 mixture under these thermodynamic conditions so perhaps no surprise. Structure assignment for the reaction products was given from the spectroscopic data.
Therefore, an easy access to trifluoromethyl derivative 10 was carried out by the condensation of aminopyrimidine 2 and trifluoroacetic acid in the presence of phosphorous oxychloride under reflux conditions for 7 hours.13-14 The product was obtained as a pair of isomers (10 and 10a) in the ratio 61:29 (based on 1H NMR data) in 40% combined yield (Scheme 2). The structures proposed for the reaction products were confirmed with the aid of spectroscopic data. 13C NMR showed a signal for a quaternary carbon at 160.1 ppm most likely to be related to the carbon attached to the trifluoromethyl group.
Moreover, reaction of 2 with cyanogen bromide (2 equiv.) in absolute ethanol containing anhydrous potassium carbonate under reflux afforded 2-amino-triazolo [1,5-c]pyrimidin-9-ol 11 as single isomer (Scheme 2).7 The formation of a single isomer perhaps is due to the fact that the reaction was not hot enough in addition to the heterogeneous base (K2CO3).
When the reaction between compound 2 and diethyl malonate15 was conducted in DMF under reflux conditions, elimination of water and ethanol occurred and gave the acetate derivatives as two isomers 12 and 12a (about 66:33) in 86% yield (Scheme 2).
Similarly, condensation between compound 2 and methyl cyanoacetate in refluxing ethanol resulted in formation of the acetonitrile derivative as an isomeric mixture 13 and 13a (77:23) in 49% yield (Scheme 2). The identities of both compounds were confirmed on the basis of spectroscopic data. For the acetate derivative 12, an IR spectrum showed stretching vibration frequencies at 3421, 1737 and 1631 cm-1 corresponding to OH, CO and C=N respectively. The 1H NMR data displayed the expected pattern for the ethoxy group at 1.16 ppm (3H, t, J 7.1, CH3) and at 4.10 (2H, q, J 7.1, CH2O), also a signal at 3.95 ppm (2H, s, CH2CO) and the 5-H chemical shift was found to be at 9.55 ppm which is more downfield than the corresponding one in compound 2 (at 8.05 ppm).
Scheme 3.
A trial to prepare the triazepine derivative 14 through the interaction between the aminopyrimidine 2 and benzylidenemalononitrile in a basic medium was unfortunately unsuccessful, but led interestingly to compound 15 which formed as the reactants were mixed together with few drops of acetone and left at room temperature for 30 min (Scheme 3). IR spectrum showed no absorption bands for NH2 or CN groups; 1H-NMR and 13C-NMR and MS were consistent with proposed structure. Further proof was gained chemically when compound 2 was allowed to condense with benzaldehyde in acidic medium to furnish the same product 15. X-ray crystallographic analysis finally proved the structure. A proposed explanation for the formation of compound 15 is that the reaction started first with the addition of the amino group lone pair to the double bond of benzylidenemalononitrile (Micheal type addition); since malononitrile is a good leaving group, it can be ejected by addition of the imino lone pair to the benzylic carbon followed by loss of hydrogen (aerial oxidation) to furnish compound 15.
The condensation between aminopyrimidine compound 2 and aromatic aldehydes was studied next aiming to prepare analogues for compound 15 by an alternative route; the reaction was performed in ethanolic piperidine at reflux temperature. Two examples of aromatic aldehydes were chosen (p-nitrobenzaldehyde and p-anisaldehyde), in the case of first example the reaction proceeded through a condensation-addition protocol to furnish the triazolopyrimidine 16 as a single isomer in 71% yield (Scheme 3). The identity of compound 16 was proven based on its spectroscopic data which have close similarity to compound 15. On the other hand, when p-anisaldehyde was allowed to react with compound 2, unlike p-nitrobenzaldehyde, it only underwent a condensation reaction with the amino group without cyclization to afford the Schiffbase 17. 1H NMR data showed a singlet signal at 8.30 ppm (integrating for two protons) attributable to 5-H and CH=N protons and this assisting the uncyclized structure. In a similar manner, the condensation between amino-pyrimidine 2 and cyclohexanone (neat) under reflux 16 for 6 hours (TLC controlled) afforded the condensation product 18 as a fairly pure single isomer in 60% yield (Scheme 3).
With the aminopyrimidine 2 in hand, a series of fused pyrimidinotriazines could be obtained through a condensation pathway. Thus, when a mixture of compound 2 and oxalyl chloride was heated in pyridine for several hours, afforded the triazines 19 and 19a as a pair of isomers (Dimroth-type rearramgment) in 84% combined yield (Scheme 3). The isomeric mixture was in a ratio of 6:5 (both isomers look to have similar chromophores and thus is not surprise to be obtained in this ratio) as indicated from the 1H NMR spectrum which displayed all signals expected for the two isomers. Also, interaction between aminopyrimidine 2 and ethyl chloroacetate in sodium methoxide under reflux gave compound 20 as single isomer.6 Spectroscopic data were consistent with proposed structure, for example, the 1H NMR data revealed a resonance of CH2 group to be at 6.58 ppm, in addition there are two resonances for two exchangeable protons at 9.30 and 9.91 ppm (OH and NH) which are reasonable chemical shifts for such protons.
Fig. 2.X-ray Crystallographic Analysis. 11-Methyl-2,12-diphenyl-12H-chromeno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-9-ol 15.
The reaction between compound 2 and ethyl pyruvate and isatin in boiling ethanol afforded compounds 21, 21a (ratio 1:1) and 22, 22a (ratio 1:1) respectively according to 1H NMR spectra (Scheme 3).
EXPERIMENTAL
All products were dried in an oven at 100 ℃ then using high vacuum under pressure of 1 mm Hg. All melting points uncorrected and were determined on Stuart electric melting point apparatus and on a kolfer hot-stage apparatus. Infrared spectra were recorded on Bruker or Satellite 2000 spectrometer using KBr discs series Fourier Transform Infrared Spectrometer. 1H NMR spectra were recorded at Bruker DX400 (unless stated) at 400 MHz and 13C NMR spectra measured on the same instrument (unless stated) at 100.6 MHz. Mass spectra were determined on GC-MS (QP 1000 EX) SHIMADZU spectrometer. At an ionizing voltage of 70ev mass spectrometry.
General procedure for reaction between imine 1 and amines
To a stirred solution of the imine 1 (3.76 g, 10 mmol) in absolute ethanol (30 ml) was added appropriate amine (20 mmol, 2 equiv.). The mixture was stirred at room temperature and after 20 minutes, a solid started to precipitate; stirring was continued for an additional 2 h. The solid product was collected by filtration, washed with ethanol, then dried and crystallized from proper solvent to give N-aminopyrimidine 2 and the pyrimidines 3a-d.
3-Amino-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol 2
Using the general procedure, reaction between imine 1 (3.76 g, 10 mmol) and hydrazine hydrate (1.25 g, 25 mmol, 2.5 equiv.) followed by crystallization from ethanol gave the N-aminopyrimidine 2 (1.95 g, 61%), as a colorless solid m.p. 260-261 ℃; IR, νmax/cm-1, 3332 (very br), 1650, 1591; 1H NMR δH 2.20 (3H, s, CH3), 5.28 (1H, s, 5-H), 6.36 (1H, d, J 0.9, 7- (or 9-) H), 6.51 (1H, d, J 0.9, 9- (or 7-)), 6.90 (2H, br s, NH2), 7.12 (1H, t, J 7.4, 4-H-Ph), 7.23 (2H, t, J 7.4, 3- and 5-H-Ph), 7.32 (2H, d, J 7.4, 2- and 6-H-Ph), 8.05 (1H, s, 2-H), 9.78 (1H, br s, OH); 13C NMR δC 19.2 (CH3), 36.8 (5-CH), 101.1, 107.6 (7-and 9-CH), 110.0, 111.8, 114.2, (all ArC), 126.6, 128.3, 128.7 (all ArCH), 138.2 (ArC), 144.38 (2-CH), 155.2, 156.3, 157.1 (all ArC);m/z [EI] 320 (M+, 25%), 304 (100), 277 (8), 228 (30), 201 (27), 129 (10), 55 (54).
By a similar procedure, the imine 1 (0.94 g, 2.5 mmol) was reacted with other nitrogen nucleophiles (5 mmol) to furnish compounds 3a-d.
3-Benzyl-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol 3a
Using the general procedure, reaction of compound 1 with benzylamine (0.54 ml, 5 mmol, 2 equiv.) followed by crystallization from ethyl acetate gave the pyrimidine 3a (0.686 g, 69%) as a pale yellow solid, m.p. 265-267 ℃, IR, νmax/cm-1, 3355, 1639, 1623; 1H NMR δH 2.18 (3H, s, CH3), 5.01 (1H, d, J 14.9, Ha), 5.05 (1H, s, 5-H), 5.15 (1H, d, J 14.9, Hb), 6.30 (1H, s, 7- (or 9-) H), 6.42 (1H, s, 9- (or 7-) H), 6.76 (1H, br s, NH), 7.15-7.37 (10H, m, 10 x Ar- H), 8.29 (1H, s, 2-H), 9.73 (1H, br s, OH); 13C NMR δC 21.3 (6-CH3), 34.9 (5-CH), 50.0 (CH2), 87.0, 100.0 (both ArC), 107.4 (ArCH), 109.6 (ArC), 112.1, 126.8, 127.8, 128.4 128.6, 128.8 (all ArCH), 137.3, 138.3, 144.4, 150.5 (all ArC), 151.6 (2-CH), 157.0 (ArC); MS [ES] [Found: [M++H], 396.1711. C25H22N3O2 requires M, 396.1712].
3-(2-Hydroxyethyl)-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol 3b
Using the general procedure, reaction of imine 1 with ethanolamine (0.305 g, 5 mmol, 2 equiv.) followed by crystallization from ethyl acetate gave the pyrimidine 3b (0.4 g, 45%) as colorless crystals, m.p. 270 ℃, IR, νmax/ cm-1, 3443 (very br), 1644, 1593, 1429; 1H NMR δH 2.10 (3H, s, CH3), 3.51 (1H, dt, J 4.3 and 13.5, Ha), 3.60 (1H, ddd, J 3.8, 6.9 and 13.4, Hb), 3.80 (1H, ddd, J 4.0, 6.9 and 13.4, Hc), 3.95 (1H, app. dt, J 4.4, 13.5, Hd), 4.13 (1H, br s, OH), 5.10 (1H, s, 5-H), 6.38 (1H, d, J 1.9, 7- (or 9-) H), 6.45 (1H, d, J 1.9, 9- (or 7-) H), 7.0 (1H, br s, NH), 7.15 (1H, t, J 7.4, 4-H-Ph), 7.23 (2H, t, J 7.4, 3- and 5-H-Ph), 7.33 (2H, d, J 7.4, 2- and 6-H-Ph), 7.98 (1H, s, 2-H), 9.10 (1H, br s, OH); 13C NMR δC 19.4 (CH3), 36.4 (5-CH), 50.5 (CH2-N), 58.0 (CH2-O), 100.4 (ArC), 101.1, 114.2 (7- and 9-CH), 114.3 (ArC), 126.9 (4-CHPh), 128.6 (4 x ArCH), 138.3, 144.3 (both ArC), 150.9 (ArCH), 151.8, 156.9, 157.1 (all ArC); MS [Found: [M+H]+, 350.1496. C20H20N3O3 requires M 350.1505].
4-Imino-3-(methoxycarbonylamino)-6-methyl-5-phenyl-4,5-dihydro-3H-chr-omeno [2,3-d]pyrimidin-8-ylacetate 3c
Using the general procedure, reaction of compound 1 with methyl carbazate (0.45 g, 5 mmol, 2 equiv.) followed by crystallization from methanol gave the carbamate 3c (0.5 g, 47%) as colorless crystals, m.p. 186 ℃, IR, νmax/ cm-1, 3369, 3148, 1771, 1648, 1622; 1H NMR δH 2.23 (3H, s, 6-CH3), 2.26 (3H, s, CH3CO), 3.35 (1H, br s, NHCO), 3.49 (3H, s, CH3O), 5.63 (1H, s, 5-H), 6.88 (1H, d, J 2.0, 7- (or 9-) H), 7.08 (1H, d, J 2.0, 9- (or 7-) H), 7.18 (1H, t, J 7.4, 4-H-Ph), 7.30 (2H, t, J 7.4, 3- and 5-H-Ph), 7.40 (2H, d, J 7.4, 2- and 6-H-Ph), 8.45 (1H, s, 2-H), 8.60 (1H, br s, NH); 13C NMR δC 19.0 (6-CH3), 21.2 (CH3CO), 51.7 (CH3O), 99.4 (ArC), 109.08 (7- (or 9-) CH), 120.5 (ArC), 121.0 (9- (or 7-) CH), 127.8 (4-CH-Ph), 128.3 (2 x ArCH), 129.2 (2 x ArCH), 138.7, 142.1, 150.2, 150.2 (all ArC), 152.7 (ArCH), 154.1 (ArC), 158.4 (CO-NH), 169.4 (CO-O); MS [ES] [Found: [M+H]+, 421.1499. C22H21N4O5 requires M, 421.1512].
3-(2,2-Dimethoxyethyl)-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol 3d
Using the general procedure, reaction of imine 1 with 2-aminoacetaldehyde dimethyl acetal (0.52 g, 5 mmol, 2 equiv.) followed by crystallization from methanol gave the pyrimidine 3d (0.6 g, 61%) as pale yellow crystals, m.p. 270-272 ℃, IR, νmax/cm-1, 3345, 2954, 1626, 1411; 1H NMR δH 2.19 (3H, s, 6-CH3), 3.34 (3H, s, CH3O), 3.36 (3H, s, CH3O), 3.86 (1H, dd, J 6.0, 13.4, Ha), 3.95 (1H, dd, J 4.7, 13.4, Hb), 4.60 (1H, app. t, J 6.0, Hx), 5.04 (1H, s, 5-CH), 6.35 (1H, s, 7- (or 9-) H), 6.45 (1H, s, 9- (or 7-) H), 6.80 (1H, br s, NH), 7.15 (1H, t, J 7.5, 4-H-Ph), 7.23 (2H, t, J 7.5, 3- and 5-H-Ph), 7.33 (2H, d, J 7.5, 2- and 6-H-Ph), 7.95 (1H, s, 2-H), 9.75 (1H, br s, OH); 13C-NMR δC 21.3 (6-CH3), 34.8 (5-CH), 49.2 (CH2), 54.8, 54.9 (both CH3O), 99.4 (O-CH-O), 100.3 (ArCH), 107.7 (7- (or 9-) CH), 109.5 (ArC), 112.0 (9- (or 7-) CH), 126.8 (4-PhCH), 128.4 (2 x ArCH), 128.6 (2 x ArCH), 138321.4, 144.2, 150.4 (all ArC), 152.0 (ArCH), 155.2, 156.9 (both ArC); MS [ES] [Found: [M+H]+, 394.1767. C22H24N3O4 requires M, 394.1751].
N-(8-Hydroxy-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyramidin-3-yl)propionamide 4
To a solution of the N-amino-pyrimidine 2 (0.8 g, 2.5 mmol) in anhydrous DMF (10 ml) was added DCC (0.6 g, 3 mmol, 1.2 equiv.), the solution stirred at room temperature for 10 minutes, then propionic acid (0.37 ml, 5 mmol, 2 equiv.) was added and the reaction mixture stirred overnight. The precipitated dicyclohexylurea was removed by filtration, the filtrate was evaporated and the solid obtained washed with ether then crystallized from ethanol to furnish the propionamide 4 (0.6 g, 64%) as a colorless solid, m.p. 227-229 ℃, IR, νmax/cm-1, 3331, 3165, 2923, 2854, 1677, 1649, 1542; 1H NMR δH 0.80 (3H, t, J 7.5, CH3), 2.10 (3H, s, 6-CH3), 2.20 (2H, q, J 7.5, CH2), 5.15 (1H, s, 5-H), 5.78 (1H, br s, NH), 6.40 (1H, d, J 2.2, 7- (or 9-) H), 6.50 (1H, d, J 2.2, 9- (or 7-) H), 7.12 (1H, t, J 7.7, 4-H-Ph), 7.23 (2H, t, J 7.7, 3- and 5-H-Ph), 7.43 (2H, t, J 7.7, 2- and 6-H-Ph), 8.10 (1H, s, 2-H); 13C NMR δC 9.6 (CH3), 19.2 (6-CH3), 27.6 (CH2), 36.6 (5-CH), 100.4 (ArC), 101.1 (7- (or 9-) CH), 113.8 (9- (or 7-) CH), 114.3 (ArC), 126.7 (4- PhCH), 128.4 (2 x PhCH), 128.6 (2 x PhCH), 137.8 (ArC), 144.2 (ArCH), 150.6, 150.9, 156.1, 157.2 (all ArC), 175.7 (CO); m/z [ES] 320 (M+- CH3CH2CO, 100%).
4-Imino-3-isothiocyanato-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol 5
To a suspension of compound 2 (0.4 g, 1.25 mmol) in dichloromethane (25 ml) was added saturated aqueous potassium carbonate (10 ml), followed by thiophosgene (0.18 ml, 2.5 mmol, 2 equiv.). The resulting mixture was stirred at room temperature for 6 h then quenched with water (40 ml). The organic layer was separated, washed with water (2 x) and brine, then dried over sodium sulphate and filtered. The solvent was evaporated and the residue crystallized from ethanol furnishing the isothiocyanate derivative 5 (0.270 g, 59%) as orange crystals, m.p. > 300 ℃, IR, νmax/cm-1, 3451, 1628, 1593; 1H NMR δH 2.11 (3H, s, CH3), 5.25 (1H, s, 5-H), 6.43 (1H, d, J 2.2, 7- (or 9-) H), 6.50 (1H, d, J 2.2, 9- (or 7-) H), 7.14 (1H, t, J 7.3, 4-H-Ph), 7.25 (2H, d, J 7.3, 3- and 5-H-Ph), 7.33 (2H, d, J 7.3, 2- and 6-H-Ph), 8.21 (1H, s, 2-H); 13C-NMR δC 19.3 (CH3), 38.2 (5-CH), 101.9 (7-CH), 115.1 (9-CH), 127.55 (4-PhCH), 128.8 (2 x PhCH), 129.0 (2 x ArCH), 172.5 (CS), (remaining quaternary carbons unclear); MS [ES] [Found: [M+H]+, 363.0907. C19H15N4O2S requires M, 363.0916].
9-Hydroxy-11-methyl-12-phenyl-3,12-dihydro-2H-chromeno[3,2-e][1,2,4]triazolo-[1,5-c]pyrimidin-2-one 6
A mixture of the N-amino-pyrimidine 2 (0.40 g, 1.25 mmol) and ethyl chloroformate (0.46 ml, 2.5 mmol, 2 equiv.) in anhydrous DMF (10 ml) was refluxed for 1 h. The mixture was then cooled, diluted with cold water (50 ml), the solid obtained collected by filtration, washed with cold water, then dried and crystallized from DMF to give the triazolopyrimidinone 5 (0.30 g, 69%) as a colorless solid, m.p. 288 ℃, IR, νmax/cm-1, 3249, 1632, 1595, 1564; 1H NMR δH 2.08 (3H, s, CH3), 5.60 (1H, s, 12-H), 6.52 (1H, d, J 2.3, 8- (or 10-) H), 6.60 (1H, d, J 2.3, 10- (or 8-) H), 7.15 (1H, t, J 7.3, 4-H-Ph), 7.23 (2H, t, J 7.3, 3- and 5-H-Ph), 7.32 (2H, d, J 7.3, 2- and 6-H-Ph), 8.58 (1H, s, 5- H), 9.60 (1H, s, NH), 9.79 (1H, s, OH); 13C NMR δC 19.2 (CH3), 37.6 (12-CH), 101.3 (8- (or 10-) CH), 103.7, 11.32 (both ArC), 114.9 (10- (or 8-) CH), 127.6 (4-PhCH), 128.5 (2 x ArCH), 128.7 (2 x ArCH), 138.6, 140.5 (both ArC), 143.5 (5-CH), 151.5, 152.2, 153.6, 156.8 (all ArC), 157.6 (CO); m/z [APCI] 331(M-NH, 100%).
9-Hydroxy-11-methyl-12-phenyl-3,12-dihydro-2H-chromeno[3,2-e][1,2,4]triazolo-[1,5-c]pyrimidine-2-thione 7 and 9-hydroxy-11-methyl-12-phenyl-2-H-chromeno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine-3(12H)-thione 7a
The N-amino-pyrimidine 2 (0.80 g, 2.5 mmol) was added to an alcoholic solution of potassium hydroxide (0.28 g, 5 mmol, 2 equiv. in 30 ml ethanol) followed by addition of carbon disulphide (2 ml, excess). The resulting mixture was refluxed for 18 h. After cooling, the precipitate was removed by filtration, the filtrate largely evaporated, the residue diluted with water (40 ml) and the resulting solution acidified with 2M HCl. The solid obtained was collected by filtration, washed several times with cold water, then dried and crystallized from methanol furnishing the triazolopyrimidinthione as a pair of isomers 7 and 7a (77/23, major/minor) (0.320 g, 24%) as pale yellow crystals, m.p. 223-225 ℃, IR, νmax/cm-1, 3477, 3388, 1618, 1559, 1428; 1H NMR δH 2.13 (3H, s, CH3, major isomer), 2.18 (3H, s, CH3, minor isomer), 5.22 (1H, s, 12-H, major isomer), 5.29 (1H, s, 12-H, minor isomer), 6.42 (1H, d, J 2.3, 8- (or 10-) H), 6.59 (1H, d, J 2.3, 10- (or 8-) H), 6.90 (1H, br s, NH, minor isomer), 7.0 (1H, br s, NH, major isomer), 7.15 (1H, t, J 7.3, 4-H-Ph), 7.23 (2H, t, J 3.7, 3-and 5-HPh), 7.32 (2H, d, J 7.7, 2-and 6-H-Ph), 8.05 (1H, s, 5-H, major isomer), 8.07 (1H, s, 5-H, minor isomer), 9.63 (1H, s, OH, major isomer), 9.78 (1H, s, OH, minor isomer); 13C NMR, δC 20.5 (CH3), 34.0 (12-CH), 97.2 (ArC), 109.9 (2 x 8-and 10-CH), 111.4 (ArC), 126.8 (4-PhCH), 128.4 (4 x ArCH), 143.7, 143.9, 152.3 (ArC), 156.8 (5-CH), 157.2, 162.5, 162.8 (all ArC).
11-Methyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-9-ol 8 and 11-methyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidin-9-ol 8a
The N-amino-pyrimidine 2 (0.40 g, 1.25 mmol) was dissolved in formic acid (10 ml) and the solution was refluxed for 12 h. The mixture was allowed to cool, then poured into ice cold water with stirring. The solid obtained was collected by filtration, washed with water, then dried and crystallized from ethanol furnishing the triazolopyrimidine as a pair of isomers 8 and 8a (51/49, major/minor) (0.30 g, 73%) as a colorless solid, m.p. 270 ℃, IR, νmax/cm-1, 3345, 3062, 1629, 1591, 1503; 1H NMR δH 2.10 (3H, s, CH3), 2.25 (3H, s, CH3, minor isomer), 5.61 (1H, s, 12-H), 5.65 (1H, s, 12-H, minor isomer), 6.49 (1H, app. s, 8- (or 10-) H), 6.62 (1H, s, 10- (or 8-) H), 6.50 (1H, d, J 2.3, 8- (or 10-) H, minor isomer), 6.60 (1H, d, J 2.3, 10- (or 8-) H, minor isomer), 7.09-7.37 (10H (both isomers), m, 10 x Ar-H), 8.55 (1H, s, 5-H), 8.57 (1H, s, 5-H, other isomer), 9.57 (1H, s, 2-H), 9.59 (1H, s, 2-H, minor isomer), 9.90 (1H, br s, OH); 13C NMR δC 19.2, 21.2 (CH3, both isomers), 35.3, 37.5 (12-CH, 2 isomers), 101.3 (ArC), 103.4, 103.6 (8- (or 10-) CH, both isomers), 107.9, 108.1 (both ArC), 112.0, 112.4 (10- (or 8-) CH, both isomers), 114.8 (ArC), 126.9, 127.1 (4-PhCH, both isomers), 128.3, 128.5 (3- and 5-PhCH, both isomers), 128.6, 128.7 (2- and 6-PhCH, both isomers), 138.6, 139.0, 140.5 (all ArC), 143.5, 143.9 (both ArCH), 151.3, 151.5, 152.2, 152.3, 153.6, 154.3, 155.3 (all ArC), 156.8, 156.9 (both ArCH), 157.6 (ArC); MS [ES] [Found: [M+H]+, 331.1188. C19H15N4O2 requires M, 331.1195].
2,11-Dimethyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo-[1,5-c]pyrimidin-9-ylacetate 9 and 2,11-Dimethyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[4,3,-c]py rimidin-9-yl acetate 9a
Compound 2 (0.40 g, 1.25 mmol) was added to a mixture of acetic acid (20 ml) and acetic anhydride (5 ml) and the resulting mixture refluxed for 12 h. After cooling, the solvent was evaporated, the residue treated with ether, the solid formed filtered, washed with ether, then dried and crystallized from dichloromethane to give the acetate as a pair of isomers 9 and 9a (51/49, major/minor) (0.40 g, 83%) as a colorless solid, m.p. 204 ℃, IR, νmax/cm-1, 3037, 1773, 1750, 1624, 1593; 1H NMR δH 2.12 (3H, s, 11-CH3), 2.17 (3H, s, 11-CH3, other isomer), 2.23 (3H, s, 2-CH3), 2.27 (3H, s, 2-CH3, minor isomer), 2.38 (3H, s, CH3CO), 2.42 (3H, s, CH3CO, minor isomer), 5.45 (1H, s, 12-H), 5.62 (1H, s, 12-H, minor isomer), 6.73 (1H, app. s, 8- (or 10-) H), 6.79 (1H, app. s, 10- (or 8-) H), 7.0-7.32 (10H (both isomers), m, 10 x Ar-H), 9.50 (1H, s, 2-H), 9.52 (1H, s, 2- H- minor isomer); 13C NMR δC 14.6, 19.0, 21.0, 21.2 (all CH3, both isomers), 36.2, 37.7 (12-CH, both isomers), 101.7 (ArC), 102.7 (8- (or 10-) CH), 108.8 (ArC), 115.0 (10- (or 8-) CH), 119.5, 120.6 (both ArC), 127.3, 127.4 (4-PhCH, both isomers), 128.4, 128.6, 128.7, 128.9 (2,3,5,6- PhCH, both isomers), 139.0, 139.5, 140.0, 142.7 (all ArC), 150.2, 151.0 (both 5-CH), 166.5, 169.3 (both CO); MS [EI] [Found: [M]+, 386.1369. C22H18N4O3 requires M, 386.1379].
11-Methyl-12-phenyl-2-(trifluoromethyl)-12H-chromeno[3,2-e][1,2,4]triazolo[1,-5-c]pyrimidin-9-ol 10 and 11-methyl-12-phenyl-3-(trifluoromethyl)-12H-chromeno-[3,2-e]-[1,2,4]triazolo[4,3-c]pyrimidin-9-ol 10a
Compound 2 (0.4 g, 1.25 mmol) was dissolved in trifluoroacetic acid (10 ml) followed by the addition of POCl3 (5 ml) portionwise with shaking; the resulting hot mixture was refluxed for 7 h. After cooling, a sticky solution formed which was dissolved in DMF. Water (50 ml) was added and the mixture was neutralized with solid potassium carbonate. The solid formed was filtered off, washed with water, dried and crystallized from DCM to give the triflouromethyltriazolopyrimidine as a pair of isomers 10 and 10a (69/21, major/minor) (0.20 g, 40%) as a colorless solid, m.p. 252-253 ℃, IR, νmax/cm-1, 3343 (br), 1650, 1484, 1428; 1H NMR δH 2.05 (3H, s, CH3-minor isomer) 2.09 (3H, s, CH3-major isomer), 5.59 (1H, s, 12-H-minor isomer) 5.65 (1H, s, 12-H- major isomer), 6.48 (1H, d, J 2.3, 8- (or 10-) H,minor isomer), 6.50 (1H, d, J 2.3, 8- (or 10-) H, major isomer), 6.58 (1H, d, J 2.3, 10- (or 8-) H, minor isomer), 6.60 (1H, d, J 2.3, 10- (or 8-) H), major isomer), 7.12 (1H, t, J 7.2, 4-H-Ph), 7.25 (2H, t, J 7.2, 3- and 5-H-Ph), 7.33 (2H, d, J 7.2, 2- and 6-H-Ph), 9.60 (1H, s, 5-H, minor isomer), 9.71 (1H, s, 5-H, major isomer), 9.78 (1H, br s, OHminor isomer), 9.85 (1H, br s, OH-major isomer); 13C NMR δC 19.1 (CH3), 38.7 (12-CH), 58.2 (C), 100.5 (8- (or 10-) CH), 112.8 (ArC), 114.2 (10- (or 8-) CH), 121.1 (ArC), 126.7 (4-PhCH), 127.3 (2 x 3- and 5-PhCH), 128.9 (2 x 2- and 6- PhCH), 138.1 (5-CH), 146.0, 150.3, 157.1, 160.1 (all ArC); 19F NMR δF, -63.7 (3F, s, major isomer), -69.0 (3F, s, minor isomer); MS [EI] [Found: [M+H]+, 399.1051. C20H14F3N4O2 requires M, 399.1069].
2-Amino-11-methyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[1,5-c]pyramidin-9-ol 11
To a stirred solution of the N-amino-pyrimidine 2 (0.40 g, 1.25 mmol) in absolute ethanol (20 ml) was added anhydrous potassium carbonate (0.51 g, 3.75 mmol, 3 equiv.) followed by cyanogen bromide (0.53 g, 2.5 mmol, 2 equiv.). The reaction mixture was then refluxed for 15 h, cooled, diluted with water and acidified with 2M HCl. The solid obtained filtered, washed with water, then dried and crystallized from methanol to afford the aminotriazolopyrimidine 11 (0.395 g, 91%) as a pale brown solid, m.p. 182-184 ℃, IR, νmax/cm-1, 3482, 3358, 3227, 2923, 2854, 1632, 1597; 1H NMR δH 2.17 (3H, s, CH3), 5.40 (1H, s, 12-H), 6.48 (1H, d, J 2.1, 8- (or 10-) H), 6.62 (2H, s, NH2), 6.58 (1H, d, J 2.1, 10- (or 8-) H), 7.12 (1H, t, J 7.3, 4-H-Ph), 7.20 (2H, t, J 7.3, 3-and 5-H-Ph), 7.25 (2H, d, 7.3, 2-and 6-H-Ph), 9.05 (1H, s, 5-H), 9.74 (1H, br s, OH); 13C NMR δC 19.2 (CH3), 37.4 (12-CH), 100.8 (ArC), 101.3 (8- (or 10-) CH), 112.6 (ArC), 114.5 (10- (or 8-) CH), 127.0 (4-PhCH), 128.3 (2 x 3- and 5-PhCH), 128.7 (2 x 2- and 6-PhCH), 137.6 (ArC), 138.3 (5-CH), 143.8, 151.7, 152.6, 153.7, 155.5, 168.2 (all ArC); MS [EI] [Found: [M]+, 345.1283. C19H15N5O2 requires M, 345.1283].
Ethyl 2-(9-hydroxy-11-methyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[1,5-c]-pyrimidin-2-yl)acetate12 and Ethyl 2-(9-hydroxy-11-methyl-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[4, 3-c] pyrimidin-3-yl)acetate 12a
Diethyl malonate (0.189 ml, 1.25 mmol) was added to a solution of compound 2 (0.40 g, 1.25 mmol) in DMF (10 ml) and the resulting mixture refluxed for 24 h. The solvent was reduced, the residue diluted with cold water (40 ml), the precipitate formed collected by filtration then washed with water, dried and crystallized from DCM giving the ester as a pair of isomers12 and12a as a pale yellow solid (0.450 g, 86%), m.p. 152-154 ℃, IR, νmax/cm-1, 3421, 1737, 1631, 1593; 1H NMR δH 1.16 (3H, t, J 7.1, CH3CH2), 2.05 (3H, s, 11-CH3-major isomer), 2.22 (3H, s,11-CH3-minor isomer) 3.95 (2H, s, CH2CO), 4.10 (2H, q, J 7.1, CH2O), 5.57 (1H, s, 12-H,major isomer), 5.62 (1H, s, 12-H, minor isomer), 6.48 (1H, s, 8- (or 10-) H,minor isomer), 6.05 (1H, d, J 1.9, 8- (or 10-) H, major isomer), 6.61 (1H, d, J 1.9, 10- (or 8-) H, major isomer), 6.64 (1H, 10- (or 8-) H, minor isomer), 7.15-7.35 (10H, m, 10 x Ar-H, both isomers), 9.55 (1H, s, 5-H), 9.80 (1H, br s, OH- major isomer), 9.90 (1H, br s, OH-minor isomer); MS [EI] [Found: [M]+, 416.1470. C23H20N4O4 requires M, 416.1485].
2-(9-Hydroxy-11-methyl-12-phenyl-12H-chromeno-[3,2-e][1,2,4]triazolo[1,5-c]pyramidin-2-yl)acetonitrile 13 and 2-(9-Hydroxy-11-methyl-12-phenyl-12H-chromeno[3,2-e]-[1,2,4]triazolo[4,3-c]-pyrimidin-3-yl)acetonitrile 13a
A mixture of compound 2 (0.40 g, 1.25 mmol) and methyl cyanoacetate (0.12 ml, 1.25 mmol) in absolute ethanol (20 ml) was heated under reflux overnight. The solvent was evaporated, the residue was suspended in ether (30 ml), the solid which crystallized out collected by filtration, washed with ether and finally purified by crystallization from DCM giving the acetonitrile as a pair of isomers 13 and 13a (0.225 g, 49%) as a yellow solid, m.p. 202-204 ℃, IR, νmax/cm-1 3421,3330,1631, 1593. 1H NMR δH 2.02 (3H, s, CH3), 4.25 (2H, s, CH2), 5.40 (1H, s, 12-H), 6.22 (1H, s, 8- (or 10-) H), 6.39 (1H, s, 10- (or 8-) H), 6.90 (1H, t, J 7.7, 4-H-Ph), 7.0 (2H, t, J 7.7, 3- and 5-H-Ph), 7.05 (2H, d, J 7.7, 2- and 6-H-Ph), 9.32 (1H, s, 5-H), 9.64 (1H, br s, OH); 13C NMR δC 18.4 (CH2), 21.3 (CH3), 35.4 (12-CH), 103.5 (ArC), 108.0 (8- (or 10-) CH), 108.3 (ArC), 112.6 (10- (or 8-) CH), 117.0 (ArC), 127.1 (4-PhCH), 128.6 (2 x ArCH), 128.7 (2 x ArCH), 139.2 (ArC), 140.5 (5-CH), 143.9, 151.3, 153.4, 155.0, 155.1, 161.2 (all ArC); m/z [ES] 370 ((M+H+), 100%).
11-Methyl-2,12-diphenyl-12H-chromeno[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-9-ol 15
The N-amino-pyrimidine 2 (0.40 g, 1.25 mmol) was mixed with benzylidenemalononitrile (0.145 g, 1.25 mmol.), to which was added a few drops of either ethanol or acetone. The mixture was shaken vigorously for 10 minutes then left at room temperature for 30 minutes. The resulting yellow solid was collected and crystallized from ethanol then ethyl acetate to furnish the triazolopyrimidine 15 (0.380 g, 74.8%) as pale yellow crystals, m.p.> 300 ℃, IR, νmax/cm-1, 3276, 1632, 1593, 1518; 1H NMR δH 2.10 (3H, s, CH3), 5.69 (1H, s, 12-CH), 6.55 (1H, d, J 2.1, 8- (or 10) H), 6.60 (1H, d, J 2.1, 10- (or 8-) H), 7.12 (1H, t, J 7.5, Ar-H), 7.27 (2H, t, J 7.5, 2 x Ar-H), 7.38 (2H, d, J 7.5, 2 x Ar-H), 7.55 (3H, m, 3 x Ar-H), 8.25 (2H, dd, J 2.7 and 7.7, 2 x Ar-H), 9.60 (1H, s, 5-H), 9.80 (1H, br s, OH); 13C NMR δC 19.3 (CH3), 37.7 (12-CH), 101.5 (8- (or 10-) CH), 103.4, 112.2 (both ArC), 115.0 (10- (or 8-) CH), 127.3, 127.7, 128.7, 128.9, 129.5 (all ArCH), 130.1 (ArC), 131.4 (ArCH) 138.7 (ArC), 140.4 (5-CH), 143.7, 151.7, 153.4, 153.9, 157.7, 165.8 (all ArC); MS [EI] [Found: [M]+, 406.1431. C23H20N4O4 requires M, 406.1430].
General procedure for reaction of N-amino-pyrimidine 2 with aromatic aldehydes to give compounds 16 and 17
An appropriate aromatic aldehyde (1.25 mmol.) was added to a solution of the N-amino-pyrimidine 2 (0.40 g, 1.25 mmol) in absolute ethanol (15 ml) containing a few drops of piperidine, the resulting mixture refluxed for 5h. The solids formed on hot in case of compound 16 and after cooling in case of compound 17 were collected by filtration, washed with ether and crystallized from proper solvent.
11-Methyl-2-(4-nitrophenyl)-12-phenyl-12H-chromeno[3,2-e][1,2,4]triazolo[1,-c]pyrimidin-9-ol 16
Using the general procedure, reaction of compound 2 with p-nitrobenzaldehyde (0.188 g, 1.25 mmol) followed by crystallization from methanol to give the triazolopyrimidine 16 (0.40 g, 71%) as yellow crystals, m.p. >300 ℃,IR, νmax/cm-1, 3313, 2963, 2846, 1628, 1591; 1H NMR δH 2.11 (3H, s, CH3), 5.62 (1H, s, 12-H), 6.47 (1H, d, J 2.2, 8- (or 10-) H), 6.60 (1H, d, J 2.2, 10- (or 8-) H), 7.15 (1H, t, J 7.5, 4-H-Ph), 7.25 (2H, t, J 7.5, 3- and 5-H-Ph), 7.37 (2H, d, J 7.5, 2- and 6-H-Ph), 8.32 (2H, d, J 8.0, 3- and 5-Hnitro ring), 8.50 (2H, d, J 8.0, 2- and 6-H-nitro ring), 9.56 (1H, s, 5-H), 9.78 (1H, br s, OH); 13C NMR δC 19.3 (CH3), 37.6 (12-CH), 101.5 (8- (or 10) CH), 103.6, 112.0 (both ArC), 115.1 (10- (or 8-) CH), 124.6 (2 x ArCH), 127.3 (4-PhCH), 128.6 (2 x ArCH), 128.7 (2 x ArCH), 128.9 (2 x ArCH), 135.9, 138.7 (both ArC), 140.7 (5-CH), 143.5, 149.0, 151.5, 153.6, 154.0, 157.7, 163.8 (all ArC); MS [EI] [Found: [M]+, 451.1470. C25H17N5O4 requires M, 451.1485].
(E)-4-imino-3-(4-methoxybenzylideneamino)-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno[2,3-d]pyrimidin-8-ol 17
Using the general procedure, reaction of compound 2 with p-anisaldehyde (0.17 g, 1.25 mmol) followed by crystallization from ethanol gave the Schiff base 17 (0.30 g, 55%) as a yellow solid, m.p. 276-278 ℃, IR, νmax/cm-1, 3175, 2952, 2836, 1633, 1596.3, 1564; 1H NMR δH 2.25 (3H, s, 11-CH3), 3.80 (3H, s, OCH3), 6.05 (1H, s, NH), 6.48 (1H, d, J 2.2, 8-H), 6.55 (1H, d, J 2.2, 10-H), 7.02 (2H, d, J 9.8, 2- and 6-H-anisole), 7.10 (1H, t, J 7.2, 4-HPh), 7.21 (4H, d, J 7.2, 4 x Ar-H), 7.72 (2H, d, J 9.8, 3- and 5-H-anisole), 8.30 (2H, s, 5-H + CH=N-N), 9.73 (1H, br s, OH); 13C NMR δC 19.2 (11-CH3), 34.9 (12-CH), 55.7 (OCH3), 101.5 (8- (or 10-) CH), 114.3 (10- (or 8-) CH), 114.6, 114.8 (both C), 114.9 (2 x ArCH), 127.1 (4-PhCH), 127.4 (ArC), 127.7 (2 x ArCH), 128.6 (2 x PhCH), 129.06 (2 x PhCH), 138.0 (ArC), 144.5 (5-CH), 151.2 (ArC), 156.5 (CH=N), 157.4, 161.0 (both ArC); MS [EI] [Found: [M]+, 438.1685. C21H15N5O2 requires M, 438.1692].
3-(cyclohexylideneamino)-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno-[2,3-d]pyrimidin-8-ol 18
A mixture of N-amino-pyrimidine 2 (0.40 g, 1.25 mmol) and cyclohexanone (3 ml) was heated at 100 ℃ until the reaction was complete (monitored by TLC; ca. 6 h). After cooling, the mixture was diluted with water, when an oily layer formed. The water was decanted and water (50 ml) added. The organic material was extracted into DCM (2 x) and the combined extracts washed with water and brine, then dried over sodium sulphate, filtered and the solvent evaporated. The residue was treated with ether, the solid obtained collected and crystallized from DCM to afford the Schiff base 18 (0.30 g, 60%) as a yellow solid, m.p. 238-240 ℃, IR, νmax/cm-1, 3292, 2952, 2846, 1622, 1585; 1H NMR δH 0.80-0.88 (2H, m, 4'-CH2), 1.25-1.33 (4H, m, 3'-and 5'-CH2), 1.68 (2H, t, J 7.13, 2'-CH2), 2.23 (3H, s, CH3), 2.76 (2H, t, J 7.4, 6'-CH2), 5.65 (1H, s, 12-H), 6.45 (1H, app. s, 8- (or 10-) H), 6.65 (1H, app. s, 10- (or 8-) H), 7.10 (1H, t, J 7.3, 4-H-Ph), 7.20 (2H, d, J 7.3, 3- and 5-H), 7.30 (2H, t, J 7.3, 2- and 6-H-Ph), 9.50 (1H, s, 5-H), 9.90 (1H, s, OH); 13C NMR δC 21.4 (CH3), 22.3, 27.4, 28.5, 31.3 (all CH2), 35.3 (12-CH), 102.8, 108.1 (both ArC), 108.4 (8- (or 10-) CH), 112.4 (10- (or 8-) CH), 127.0 (4-PhCH), 128.3 (2 x ArCH), 128.6 (2 x ArCH), 139.1 (ArC), 140.0 (5-CH), 144.1, 151.5, 152.9, 154.4, 155.4, 170.1 (all ArC); MS [Found: [M]+, 401.1988. C24H25N4O2 requires M, 401.1978].
10-Hydroxy-12-methyl-13-phenyl-13H-chromeno-[2,3-d]]pyrimidino[3,4-b][1,2,4]triazin-2,3-dione 19 and 10-Hydroxy-12-methyl-13-phenyl-13H-chromeno[2,3-d]]pyrimidino[4,3-c][1,2 ,4]triazin-3,4-dione 19a
Oxaloyl chloride (0.21 ml, 2.5 mmol, 2 equiv.) was added carefully to a solution of compound 2 (0.40 g, 1.25 mmol) in pyridine (10 ml) and the resulting mixture shaken at room temperature for 10 minutes then refluxed for 20 h. The solvent was reduced under vacuum, the residue poured into a mixture of crushed ice and 2M HCl. The solid precipitate was collected by filtration, washed with water, then dried and crystallized from ethanol to give the trizindione as apair of isomers 19 and 19a (55/45, major/minor) (0.39 g, 83%) as whitish-grey crystals, m.p. 220 ℃, IR, νmax/cm-1, 3167 (very br), 1649, 1588, 1566, 1493.6; 1H NMR δH 2.15 (3H, s, CH3-major isomer), 2.20 (3H, s, CH3-minor isomer), 5.55 (1H, s, 13-H-major isomer), 5.72 (1H, s, 13-H-minor isomer), 6.53 (1H, d, J 2.3, 9- (or 11-) H-major isomer), 6.56 (1H, s, 9- (or 11-) H-minor isomer), 6.60 (1H, app. s, 11- (or 9-) H-minor isomer), 6.62 (1H, d, J 2.3, 11- (or 9-) H-major isomer), 7.14 (2H, 2 overlaping t, J 7.5, 2 x Ar-H (both isomers)), 7.23 (2H, t, J 7.5, 2 x Ar- H-major isomer), 7.24 (2H, t, J 7.5, 2 x Ar-H, minor isomer), 7.36 (2H, d, J 7.4, 2 x Ar-H-major isomer), 7.42 (2H, d, J 7.4, 2 x Ar-H minor isomer), 8.65 (1H, s, 6-H-major isomer), 8.69 (1H, s, 6-H-minor isomer), 9.06 (1H, br s, NH-major isomer), 9.50 (1H, br s, NH-minor isomer), 9.95 (1H, br s, OH-major isomer), 10.25 (1H, s, OH-minor isomer); 13C NMR δC 19.0 (CH3), 21.2 (CH3-other isomer), 33.2 (13-CH), 35.0 (13-CH-other isomer), 100.3 (9- (or 11-) CH-major isomer), 102.1 (9- (or 11-) CH-minor isomer), 107.5, 108.0 (both ArC), 112.9 (11- (or 9-) CH-major isomer), 113.0 (11- (or 9-) CH-minor isomer), 127.3, 128.2, 128.3, 128.6, 129.0 (all ArCH), 138.3 (ArC), 139.2 (6-CH), 142.5, 149.7, 150.1,153.2, 156.0, 157.7, 158.2, 162.0 (all ArC); m/z for C20H14N4O4 (ES) M.
10-Hydroxy-12-methyl-13-phenyl-2H,13H-chromeno[2,3-d]]pyrimidinp[3,4-b][1,2-,4] triazin-3-one 20
Ethyl chloroacetate (0.26 ml, 2.5 mmol, 2 equiv.) was added to the N-amino -pyrimidine 2 (0.40 g, 1.25 mmol) in sodium methoxide solution (0.057 g Na in 30 ml methanol) and the reaction mixture refluxed for 12 h. After cooling, the mixture was diluted with cold water and acidified with 2 M HCl. The resulting solid product was filtered, washed with water, then dried and crystallized from methanol furnishing the triazinone 20 (0.350 g, 78%) as a yellow solid, m.p. ℃, IR, νmax/cm-1, 3380, 3203, 1628; 1H NMR δH 2.15 (3H, s, CH3), 5.60 (1H, s, 13-H), 6.50 (1H, d, J 2.3, 9- (or 11-) H), 6.58 (2H, s, CH2), 6.62 (1H, d, J 2.3, 11- (or 9-) H), 7.20 (1H, t, J 7.4, 4-H-Ph), 7.30 (2H, t, J 7.4, 3- and 5-H-Ph), 7.42 (2H, d, J 7.4, 2- and 6-H-Ph), 8.62 (1H, s, 6-H), 9.30 (1H, br s, NH), 9.91 (1H, s, OH); 13C NMR δC 19.3 (CH3), 35.0 (13-CH), 64.9 (CH2), 98.2 (ArC), 101.0 (9- (or 11-) CH), 106.6 (ArC), 113.5 (11- (or 9-) CH), 127.0 (4-PhCH), 128.2 (2 x ArCH), 128.8 (2 x ArCH), 139.5, 146.2, 148.0, 149.0, 153.3 (all ArC), 156.6 (6-CH), 172.1 (CO); m/z for C20H16N4O3 (ES) M.
10-Hydroxy-13-phenyl-3,12-dimethyl-2H,13H-chromeno[2,3-d]]pyrimidinp[3,4-b][1,2,4]triazin-2-one 21 and 10-Hydroxy-13-phenyl-3,12-dimethyl-2H,13H-chromeno[2,3-d]]pyrimidinp[4,3-c][1,2-,4]triazin-4-one 21a
To a stirred solution of compound 2 (0.40 g, 1.25 mmol) in absolute ethanol (15 ml) was added ethyl pyruvate (0.145 ml, 1.25 mmol) and the mixture refluxed for 3 h. The solid formed during heating and, after cooling, was collected by filtration, washed with ethanol, dried and crystallized from ethanol to give the triazinone as a pair of isomers 21 and 21a (51/49, major/minor) (0.30 g, 64%) as a pale violet solid, m.p. >300 ℃, IR, νmax/cm-1, 3201, 2922, 1661, 1605, 1471; 1H NMR δH 2.10 (3H, s, 12-CH3-major), 2.20 (3H, s, 12-CH3-minor isomer), 2.26 (6H, s, 2 x 3-CH3-both isomers), 5.40 (1H, s, 13-H-major isomer), 5.51 (1H, s, 13-H-minor isomer), 6.43 (1H, s, 9- (or 11-) H-major isomer), 6.46 (1H,s, 11- (or 9-) H-major isomer), 6.57 (1H, s, 9- (or 11-) H-minor isomer), 6.60 (1H, s, 11- (or 9-) H-minorisomer), 7.12 (2H, t, J 7.6, 4-H-Ph-both isomers), 7.22 (4H, t, J 7.6, 2 x 3- and 5-H-Ph-both isomers), 7.30 (4H, d, J 7.6, 4 x 2- and 6-H-Ph-both isomers), 8.98 (1H, s, 6-Hmajor isomer), 9.02 (1H, s, 6-H-minor isomer), 9.83 (1H, s, OH-major isomer), 10.0 (1H, s, OH-minor isomer); 13C NMR δC 18.1 (12-CH3), 19.2 (12-CH3-other isomer), 21.3 (2 x 3-CH3-both isomers), 33.7, 36.0 (13-CH-both isomers), 101.5 (9- (or 11-) CH), 104.6, 104.9 (both ArC), 108.09 (ArCH), 109.1, 113.03 (both ArC), 115.4 (ArCH), 126.9, 127.1 (2 x 4-PhCH-both isomers), 128.5, 128.6 (2 x PhCHboth isomers), 128.7, 129.0 (2 x PhCH-both isomers), 138.5, 139.1, 143.4, 143.9 (all ArC), 148.4 (6-CH), 150.8, 151.0, 152.6, 152.8, 155.2, 157.3, 157.6, 157.9, 158.7, 159.8, 159.9 (all ArC); MS [ES] [Found: [M+H]+, 373.1308. C20H17N4O3 requires M, 373.1301].
Reaction of compound 293 with isatin to furnish compounds 22 and 22a
A mixture of the N-amino-pyrimidine 293 (0.40 g, 1.25 mmol) and isatin (0.18 g, 1.25 mmol) in absolute ethanol (20 ml) was stirred and heated for 3 h. The solid formed during the reaction was filtered while hot, the filtrate was evaporated and the residue treated with ether to give an additional amount of the product which was combined and which crystallized from acetic acid to furnish the hexacyclic compound as a pair of isomers 320 and 320a (51/49, major/minor) (0.45 g, 83%) as red crystals, m.p. >300 ℃, IR, νmax/cm-1, 3432, 3061, 1639, 1544; 1H NMR δH 2.15 (3H, s, CH3-major isomer), 2.22 (3H, s, CH3-minor isomer), 5.68 (1H, s, 16-H-major isomer), 5.82 (1H, s, 16-H-minor isomer), 6.51 (2H, app. s, 12- and 14-H-major isomer), 6.66 (2H, d, 2.2, 12- and 14-H-minor isomer), 7.10 (2H, t, J 6.7, 4-H-Ph-both isomers), 7.15-7.24 (6H, m, 6 x Ar-H-both isomers), 7.39 (4H, d, J 7.9, 4 x Ar-Hboth isomers), 7.52-7.61 (4H, m, 4 x Ar-H-both isomers), 8.0 (2H, t, J 7.9, 2 x 6-H-both isomers), 9.40 (1H, s, 9-Hmajor isomer), 9.45 (1H, s, 9-H-minor isomer), 10.20 (1H, br s, OH); 13C NMR δC 19.1 (CH3-major isomer), 21.2 (CH3-minor isomer), 34.2, 36.4 (16-CH-both isomers), 101.4, 106.4 (both 12- (or 14-) CH-both isomers), 106.6, 107.9, 109.0 (all ArC), 112.9, 115.3 (both 14- (or 12-) CH-both isomers), 119.4, 119.5, 122.4, 123.6, 126.8, 127.0, 128.3, 128.6, 128.7, 129.0 (all ArCH), 134.7 (ArC), 138.3, 138.9 (both 9-CH-both isomers), 143.5, 144.0, 146.7, 146.9, 148.3, 149.0, 150.6, 150.8, 150.9, 150.7, 155.2, 156.4, 157.2, 157.5, 161.0 (all ArC); MS [EI] [Found: [M]+, 432.1448. C26H17N5O2 requires M, 432.1461].
참고문헌
- Ife, R. J.; Brown, T. H.; Blurton, P.; Keeling, D. J.; Leach, C. A.; Meeson, M. L.; Prsons, M. E. Theobald, J. Med. Chem. 1995, 38, 2763. https://doi.org/10.1021/jm00014a027
- Alexander, F. ARKIVOC 2010, 4, 1.
- Abass, M.; Ismail, M. M.; Abdel-Monem, W. R.; Mayas, A. S. J. Serb. Chem. Soc. 2010, 75(1), 11. https://doi.org/10.2298/JSC1001011A
- Ostrowski, S. Jordan. J. of Chemistry 2009, 4, 1.
- Jones, A. S.; Sayers, J. R.; Walker, R. T.; De Clercq, E. J. Med. Chem., 1988, 31, 268 https://doi.org/10.1021/jm00396a043
- Griengl, H.; Wanek, E.; Schwarz, W.; Streicher, W.; Rosenwirth, B.; De Clercq, E. J. Med. Chem., 1987, 30, 1199 https://doi.org/10.1021/jm00390a013
- De Clercq, E.; Bernaerts, R. J. Bio. Chem., 1987, 262, 14905
- Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E.; Desmyter, J.; Vandebutte, M. Biochem. Biophys. Res. Commun., 1987, 142, 128 https://doi.org/10.1016/0006-291X(87)90460-8
- De Clercq, E. Anticancer Res., 1986, 6, 549.
- Varaprasad, C. V. N. S.; Barawkar, D.; El Abdellaoui, H.; Chakravarty, S.; Allan, M.; Chen, H.; Zhang, W.; Wu, J. Z.; Tam, R.; Hamatake, R.; Lang, S.; Hong, Z. Bioorg. Med. Chem. Lett., 2006, 16, 3975. https://doi.org/10.1016/j.bmcl.2006.05.019
- El-Agrody, A. M.; Abd El-Latif, M. S.; Fakery, A. H.; Bedair, A. H. Molecules 2001, 6, 519. https://doi.org/10.3390/60600519
- Hassan, N. A. Molecules 2000, 5, 826. https://doi.org/10.3390/50600826
- Agrody, A. M.; Hassan, S. M. J. Chem. Res. (S) 1995, 100.
- Bakeer, H. M.; Mohammed, F. K. Egypt. J. Chem. 2008, 51, 325.
- Dimroth, O. Justus Liebig's Annalen der Chemie 1909, 364, 183. https://doi.org/10.1002/jlac.19093640204
- Rashad, A. E.; Heikal, O. A.; El-Nezawy, O. A. H.; Abdel-Megeid, F. M. E. Heteroatom Chemistry 2005, 16, 226. https://doi.org/10.1002/hc.20114
- Ioakes, D.; Brown, D. M.; Salisbury, S. A. J. Chem. Soc. Perkin Trans 1999, 1, 1333.
- Wolf-Diethard, P.; Annemarie, H.; Pavel, P.; Anja, B.; Jana, M. J. Heterocyclic Chem. 1999, 36, 1327. https://doi.org/10.1002/jhet.5570360536
- Zaki, M. E. A.; Fawzy, N. M.; Swelam, S. A. Molecules Online [Electronic Publication] 1999, 3, 1. https://doi.org/10.1007/s007830050070
- Tverdokhlebov, A. V.; Zavada, A. V.; Tolmachev, A. A.; Kostyuk, A. N.; Chernega, A. N.; Rusanov, E. B. Tetrahedron 2005, 61, 9618. https://doi.org/10.1016/j.tet.2005.07.074
피인용 문헌
- 3-Amino-8-hydroxy-4-imino-6-methyl-5-phenyl-4,5-dihydro-3H-chromeno [2,3-d ]pyrimidine: An Effecient Key Precursor for Novel Synthesis of Some Interesting Triazines and Triazepines as Potential Anti-Tumor Agents vol.17, pp.12, 2012, https://doi.org/10.3390/molecules171011538
- Synthesis, reactions and applications of pyranotriazolopyrimidines vol.5, pp.4, 2014, https://doi.org/10.5155/eurjchem.5.4.681-694.1087